BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scarpignato C, Hongo M, Wu JCY, Lottrup C, Lazarescu A, Stein E, Hunt RH. Pharmacologic treatment of GERD: Where we are now, and where are we going? Ann N Y Acad Sci 2020;1482:193-212. [PMID: 32935346 DOI: 10.1111/nyas.14473] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Sintusek P, Mutalib M, Thapar N. Gastroesophageal reflux disease in children: What’s new right now? World J Gastrointest Endosc 2023; 15(3): 84-102 [DOI: 10.4253/wjge.v15.i3.84] [Reference Citation Analysis]
2 Bai X, Ding SQ, Zhang XP, Han MH, Dai DQ. Exposure to Commonly Used Drugs and the Risk of Gastric Cancer: An Umbrella Review of Meta-Analyses. Cancers (Basel) 2023;15. [PMID: 36672322 DOI: 10.3390/cancers15020372] [Reference Citation Analysis]
3 Schlottmann F, Herbella FAM, Patti MG. Gastroesophageal reflux disease and dysphagia. Dysphagia 2023. [DOI: 10.1016/b978-0-323-99865-9.00011-7] [Reference Citation Analysis]
4 Romano C, Scarpignato C. Pharmacologic treatment of GERD in adolescents: Is esophageal mucosal protection an option? Therap Adv Gastroenterol 2022;15:17562848221115319. [PMID: 36004307 DOI: 10.1177/17562848221115319] [Reference Citation Analysis]
5 Ghoshal UC, Blaachandran A, Rai S, Misra A. Nocturnal acid breakthrough and esophageal acidification during treatment with dexlansoprazole as compared to omeprazole in patients with gastroesophageal reflux disease. Indian J Gastroenterol 2022;41:405-14. [PMID: 35771390 DOI: 10.1007/s12664-022-01270-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Scarpignato C. Acid-Lowering Drugs for the Treatment of Gastro-esophageal Reflux Disease. Gastroesophageal Reflux in Children 2022. [DOI: 10.1007/978-3-030-99067-1_22] [Reference Citation Analysis]
7 Domingues G, Moraes-Filho JPP. GASTROESOPHAGEAL REFLUX DISEASE: A PRACTICAL APPROACH. Arq Gastroenterol 2021;58:525-33. [PMID: 34909861 DOI: 10.1590/S0004-2803.202100000-94] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Niu CY, Luo XC. Application of potassium competitive acid blockers in acid-related diseases. Shijie Huaren Xiaohua Zazhi 2021; 29(8): 383-388 [DOI: 10.11569/wcjd.v29.i8.383] [Reference Citation Analysis]
9 Savarino V, Marabotto E, Zentilin P, Demarzo MG, de Bortoli N, Savarino E. Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art. Drug Des Devel Ther 2021;15:1609-21. [PMID: 33907381 DOI: 10.2147/DDDT.S306371] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
10 Muntingh G. Gastro-oesophageal reflux disease: extinguishing that fire. South African General Practitioner 2021;2:178-183. [DOI: 10.36303/sagp.2021.2.5.0099] [Reference Citation Analysis]